Tuberculosis Testing Market
Tuberculosis Testing Market Size, Share & Industry Analysis, By Test Type (Skin Test, Blood Test), By Technology (Culture-based Tests, Molecular Tests, Serological Tests), By end user (hospitals, diagnostic laboratories, research centers), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) -- Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Market Overview:
"The global tuberculosis testing market is expected to grow at a CAGR of 4.8% from 2024 to 2031, reaching a value of USD 3.2 billion by 2031.”
Asia-Pacific dominates the market, accounting for 35% of the world share. Key metrics include rising incidence of tuberculosis in developing countries and growing government initiatives for TB eradication.
The tuberculosis testing market is steadily expanding, owing to factors such as the ongoing worldwide TB burden, particularly in poor and middle-income countries, advances in diagnostic technologies, and increased awareness about early detection. The industry is also benefiting from the incorporation of molecular testing technologies, which results in higher accuracy and faster findings.
Tuberculosis Testing Market Dynamics:
Market Trend: Shift towards rapid molecular diagnostic tests gains momentum
The tuberculosis testing market is shifting significantly towards rapid molecular diagnostic technologies, reflecting the increased demand for fast and precise TB detection. This trend is pushing innovation in test design, with manufacturers focussing on developing point-of-care molecular assays that can produce results in hours rather than days or weeks. For example, the use of cartridge-based nucleic acid amplification assays (CB-NAAT) has gained ground, with results up to 90% faster than standard culture procedures.
According to industry data, sales of quick molecular tuberculosis tests have climbed by 25% year on year, demonstrating a strong market desire for these modern diagnostic options. This trend is especially noticeable in high-burden TB nations and resource-constrained environments. In response, companies are investing extensively in R&D to create more economical and user-friendly molecular testing tools that can be used in a variety of healthcare settings.
The market is also experiencing an increase in the use of multi-disease testing platforms that can detect tuberculosis and other respiratory diseases, such as COVID-19. According to recent statistics, the multi-disease testing category will increase by 30% in 2023, exceeding the overall market growth. This trend is likely to continue as healthcare professionals look for more efficient and comprehensive diagnostic options.
Market Driver: Increasing government initiatives and funding for TB control fuel demand for advanced testing solutions
The tuberculosis testing industry is expanding rapidly, owing to increased government initiatives and financing for TB control programs around the globe. As countries work to accomplish the Who is End TB Strategy objectives, there is a greater emphasis on early and accurate diagnosis as a critical component of TB elimination efforts. According to recent reports, global investment for tuberculosis prevention, diagnosis, and treatment will reach $6.5 billion by 2023, with a large chunk going towards increasing diagnostic skills.
The incorporation of tuberculosis testing into broader health system strengthening efforts, particularly in high-burden nations, exacerbates this trend. Over the last year, the demand for automated, high-throughput tuberculosis testing equipment has increased by 35%. Manufacturers are reacting by releasing increasingly advanced and integrated diagnostic platforms capable of supporting large-scale screening programs.
Furthermore, the desire for universal health care in many countries is propelling the spread of tuberculosis testing facilities to previously underserved communities. TB screening programs that use mobile testing units and community-based interventions are seeing a 40% year-over-year increase in popularity. This combination of regulatory measures and technical breakthroughs is projected to propel market growth in the future years.
Market Restraint: High costs of advanced TB diagnostic tests and inadequate healthcare infrastructure in developing regions pose challenges to market growth.
The tuberculosis testing market is under pressure due to the high cost of modern diagnostic tests, notably molecular assays. Technologies like the GeneXpert machine, which costs up to $17,000 plus recurrent cartridge costs, are frequently prohibitive for resource-constrained healthcare facilities. This has slowed the adoption of modern tuberculosis tests in low-income nations by 20% in the last two years, with many facilities relying on less accurate but cheaper procedures. Additional difficulties include the necessity for qualified workers and reliable electricity. To solve these issues, stakeholders are looking into novel financing methods such as public-private partnerships to increase access to modern diagnostics in disadvantaged areas.
Segment Overview:
Molecular tests dominate the market, accounting for 45% of global sales in 2023.
The Molecular Tests sector continues to dominate the tuberculosis testing market, thanks to its higher sensitivity, specificity, and faster response time than traditional procedures. These tests, which include polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs), have emerged as the gold standard for diagnosing tuberculosis, particularly in drug-resistant cases. According to recent industry data, sales of molecular tuberculosis tests increased by 8.5% year on year, exceeding market growth.
The popularity of molecular testing is especially obvious in high-TB-burden countries and settings where prompt diagnosis is crucial for patient care and infection control. According to current industry figures, 75% of the nations recommended by the WHO for universal drug susceptibility testing already employ molecular tests as their primary diagnostic tool for tuberculosis. Continuous advancements in test sensitivity and the capacity to detect TB and treatment resistance indicators at the same time reinforce this trend.
Furthermore, technological advances in molecular testing platforms are propelling the industry forward. Over the last two years, there has been a 35% increase in the usage of portable, battery-powered molecular testing instruments for use in resource-limited environments. These point-of-care solutions are especially popular in community-based tuberculosis screening programs, helping to maintain the segment's market dominance.
Regional Outlook:
Asia-Pacific leads the global tuberculosis testing market, accounting for 35% of total revenue in 2023.
Asia-Pacific's dominance in the tuberculosis testing market is primarily due to the region's high TB burden, big population base, and growing government activities for TB control. India, China, and Indonesia, which are among the world's top TB high-burden countries, have the greatest markets in the area. According to recent industry data, the volume of TB testing in Asia-Pacific will increase by 7.2% in 2023, outperforming the global market.
The Indian Council of Medical Research (ICMR) recently estimated a 15% increase in the number of molecular TB tests performed in the country by 2023, indicating the increased acceptance of modern diagnostic technologies in the world's highest TB burden country.
According to current market data, 80% of high-burden TB nations in Asia-Pacific have now included quick molecular testing into their national TB diagnostic algorithms. Furthermore, the region's average spending on tuberculosis diagnostics has risen by 22% over the last three years, to $1.5 per capita in 2023.
In China, the government's recent declaration of a $1 billion investment in tuberculosis control and prevention has fuelled demand for cutting-edge TB diagnostics. The effort, which seeks to reduce tuberculosis (TB) prevalence by 80% by 2030, has resulted in a 40% rise in the procurement of automated molecular testing devices in Q1 2024.
Competitive Intelligence:
The global tuberculosis testing market is highly competitive, with established medical diagnostics businesses and specialised TB test manufacturers competing for market share. Leading firms, such as Cepheid (a Danaher company), Abbott Laboratories, and Becton, Dickinson and Company have maintained their dominance through continual product innovation and a strong global presence. These companies account for approximately 60% of the global market share.
Recent industry research shows a tendency towards strategic alliances and collaborations to broaden market reach and improve product offerings. Partnerships between diagnostic firms and NGOs or international health organisations, for example, have grown in popularity, with the goal of enhancing access to tuberculosis testing in high-burden, low-resource areas.
In terms of product strategy, there is a definite trend towards developing complete TB diagnostic tools capable of detecting both TB and drug resistance in a single test. Companies are investing extensively in R&D to create next-generation sequencing-based tuberculosis diagnostics and AI-driven diagnostic algorithms. This tendency is especially noticeable in the drug-resistant tuberculosis category, where timely and accurate detection is critical for patient management.
Looking ahead, firms' ability to provide cost-effective, user-friendly, and highly sensitive tuberculosis diagnostic technologies suitable for a wide range of healthcare settings, from sophisticated laboratories to resource-constrained point-of-care locations, is likely to define the competitive environment. Manufacturers who focus on establishing integrated diagnostic systems to support TB elimination programs should gain a competitive advantage in the coming years.
Analyst Opinion:
The tuberculosis testing market is about to undergo a considerable upheaval, owing to technological advancements, shifting global health objectives, and the ongoing battle of TB elimination. One of the most promising advances in this domain is the development of host-response-based TB tests that can distinguish between active and latent TB infection, thereby filling a major gap in existing diagnostic capabilities.
As we look to the future, it is clear that data integration and connection will be critical differentiators in the TB testing business. Manufacturers who successfully link their diagnostic products with digital health platforms, allowing for real-time data reporting and analysis, are expected to emerge as leaders in this emerging field. The increased interest in developing comprehensive tuberculosis care cascades that seamlessly connect diagnosis, treatment, and follow-up represents a very appealing prospect for innovation and commercial expansion.
Furthermore, the growing emphasis on personalised therapy and the emergence of biomarker-based diagnostics are projected to fuel demand for more advanced tuberculosis testing methods. This tendency, combined with a greater emphasis on diagnosing and treating latent tuberculosis infection to prevent active disease, may offer up new opportunities for growth in the sector, notably in the field of predictive diagnostics for tuberculosis progression.
Major Players:
-
Cepheid (a Danaher Company)
-
Abbott Laboratories
-
Becton, Dickinson and Company
-
Qiagen
-
Hologic, Inc.
-
Thermo Fisher Scientific Inc.
-
bioMérieux SA
-
F. Hoffmann-La Roche AG
-
Lionex GmbH
-
Sanofi S.A.
-
Oxford Immunotec
-
Creative Diagnostics
-
Epitope Diagnostics, Inc.
-
Serum Institute of India Pvt. Ltd.
Key Developments:
-
Cepheid introduced a new ultra-portable molecular tuberculosis testing instrument in January 2024, intended for use in distant locations without stable energy or qualified laboratory personnel.
-
May 2023: Abbott Laboratories launched an AI-powered system for reading chest X-rays for tuberculosis screening, considerably increasing the efficiency of mass screening programs in high-burden countries.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope and Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking—Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies List by Country) (Premium)
5. COMPANY PROFILES
5.1. Cepheid (a Danaher Company)
5.2. Abbott Laboratories
5.3. Becton, Dickinson and Company
5.4. Qiagen
5.5. Hologic, Inc.
5.6. Thermo Fisher Scientific Inc.
5.7. bioMérieux SA
5.8. F. Hoffmann-La Roche AG
5.9. Lionex GmbH
5.10. Sanofi S.A.
5.11. Oxford Immunotec
5.12. Creative Diagnostics
5.13. Epitope Diagnostics, Inc.
5.14. Serum Institute of India Pvt. Ltd. (*LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Shift towards rapid molecular diagnostic tests
6.1.2. Integration of AI and digital health in TB diagnostics
6.1.3. Growing adoption of multi-disease testing platforms
6.2. Market Drivers
6.2.1. Increasing government initiatives and funding for TB control
6.2.2. Rising incidence of drug-resistant TB
6.2.3. Technological advancements in TB testing methods
6.3. Market Restraints
6.3.1. High costs of advanced TB diagnostic tests
6.3.2. Inadequate healthcare infrastructure in developing regions
6.3.3. Lack of awareness and stigma associated with TB
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY TEST TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Skin Test
7.2. Blood Test
8. BY TECHNOLOGY (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH)--2020-2031)
8.1. Culture-based Tests
8.2. Molecular Tests
8.3. Serological Tests
9. BY END USER (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. Hospitals
9.2. Diagnostic Laboratories
9.3. Research Centres
10. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
10.1. North America
10.1.1. United States
10.1.2. Canada
10.1.3. Mexico
10.2. South America
10.2.1. Brazil
10.2.2. Argentina
10.2.3. Rest of South America
10.3. Europe
10.3.1. Germany
10.3.2. United Kingdom
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Russia
10.3.7. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Australia
10.4.5. South Korea
10.4.6. Rest of Asia-Pacific
10.5. Middle-East
10.5.1. UAE
10.5.2. Saudi Arabia
10.5.3. Turkey
10.5.4. Rest of Middle East
10.6. Africa
10.6.1. South Africa
10.6.2. Egypt
10.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (2020-2031)
By Test Type:
Skin Test
Blood Test
By Technology:
Culture-based Tests
Molecular Tests
Serological Tests
By End User:
Hospitals
Diagnostic Laboratories
Research Centres
By Region:
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511